To test the hypothesis that somatomedin activity is influenced by diabetes and its metabolic regulation, the relationship between somatomedin activity and diabetic control as assessed by hemoglobin A 1C was investigated in 40 children with insulin-dependent diabetes. An inverse correlation between hemoglobin A 1c and serum somatomedin activity was statistically significant. The data suggest that abnormalities of linear growth, which can occur in children with poorly controlled diabetes, may involve abnormalities in net somatomedin activity. 
G rowth impairment may complicate diabetes in children, 1 " 3 particularly when metabolic control is poor, 2 -4 but the mechanism of growth retardation is obscure. There is evidence that hormonal/nutritional contributions to growth are mediated in part by the stimulation of growth cartilage by somatomedins, 5 ' 6 and our recent studies support a major role for insulin in the regulation of circulating somatomedin activity. Rats with streptozotocin-induced diabetes have decreased somatomedin activity and poor growth, 7 -8 with an inverse correlation between somatomedin activity and indices of diabetic control. 8 Previous reports differ as to whether or not somatomedin activity is related to diabetic control in humans, 9 " 12 possibly due in part to lack of suitable markers of chronic metabolic control. Because measurements of hemoglobin A 1c (HbA 1c ) appear to provide an improved index of long-term glucose control, 13 -14 in these studies we compared levels of somatomedin activity with HbA 1c in children with insulin-dependent diabetes (IDD).
METHODS
Forty nonobese children (20 male, 20 female) with IDD were selected at random from our patient files. Mean age was 12.3 ±3.1 yr (mean ± SD) and duration of diabetes was 4.3 ± 2.7 yr. No subject had a medical problem other than diabetes, no medications other than insulin were being taken at the time of the study, and height in all was above the third percentile for age. After informed consent, and prior to injection of insulin, fasting blood was obtained for glucose, HbA 1c , and somatomedin activity. Glucose was also measured in a 24-h urine sample collected the previous day.
Glucose was measured by standard glucose oxidase methods. HbA 1c was measured using the method of Trivelli et al.; 15 normal children have 4.43 ± 0.60% HbA 1c (mean ± SD, N = 92).
Somatomedin activity (SMA) was measured by the ability of serum samples to stimulate uptake of SO 4 into pig costal cartilage as described previously.
7 ' 8 Sample potency was expressed relative to a standard serum (defined as SMA = 1.00 U/ml) from a normal adult male. Fasting values in 22 normal children aged 6 and above ranged from 0.55 to 1.62 U/ml with a mean of 0.96 ± 0.26 (mean ± 1 SD). SMA in 10 euthyroid growth hormone-deficient children ranged from 0.07 to 0.50 U/ml, with a mean of 0.27 ± 0.16 (mean ± 1 SD). 16 
RESULTS
Levels of somatomedin activity, HbA 1c , and plasma and urine glucose are shown in Table 1 . The subjects demonstrated a wide range of diabetic control on all three of the control parameters. Mean somatomedin activity in the entire group of diabetic subjects was lower than levels in normal children (P < 0.001) but significantly higher than in growth hormone-deficient children (P < 0.05). Somatomedin activity was inversely correlated with metabolic control as indicated by HbA 1c , but not with plasma or urine glucose. Somatomedin activity in 24 children with rather poor metabolic control (HbA 1c > 8.5%) ranged from 0.01 to 0.72 U/ml, with a mean of 0.40 ± 0.19 U/ml (mean ± 1 SD), still slightly higher than in growth hormone-deficient children (P < 0.05).
DISCUSSION
Prompted by clinical observations indicating that insulin may stimulate growth via somatomedins, 17 " 20 and animal studies supporting this contention, 7 ' 8 the relationship between somatomedin activity and diabetic control was examined in children with insulin-dependent, ketosis-prone diabetes. The present studies reveal depressed somatomedin activity in our group of diabetic children and a significant correlation between somatomedin activity and diabetic control, as assessed by HbA 1c (Figure 1 ). The lack of correlation with plasma and urine glucose may reflect the momentto-moment variability in glycemia in such subjects; 21 -22 HbA 1c provides a more suitable index of chronic diabetic control, 13 ' 14 and affords to this and other studies of diabetic control an advantage that has heretofore not been available.
A more modest lowering of somatomedin activity in diabetic adults was previously reported by Yde, 10 who also found a relation to plasma glucose in normal weight but not in obese subjects. Our data differ from those of Cohen et al., 12 who reported high somatomedin activity in diabetics; the discrepancy may reflect their use of a chick cartilage bioassay system, which could have a spectrum of sensitivity to growth factors that differs from that of the mammalian cartilage used here and by Yde. Decreased somatomedin activity in diabetes also represents a qualitative difference from the nonsuppressible insulin-like activity (NSILA) reported to be normal in diabetes. 23 -24 Although somatomedins do have NSILA properties, 25 recent studies indicate that assays for NSILA are relatively insensitive to somatomedins in whole serum, 26 and that the bulk of circulating NSILA is due to factors with little or no ability to stimulate mammalian cartilage.
27 - 28 Altered growth in diabetes was a common complication in the pre-insulin era 29 and has not been eradicated completely with insulin therapy.
1 " 3 The Mauriac syndrome of "diabetic dwarfism" 1 -30 is an extreme example of this problem; such subjects appear to have hypopituitary levels of somatomedin activity, which may improve with more adequate insulin therapy. 31 More recent studies suggest that stature expectations and growth velocity are close to normal in insulin-treated diabetic children, but may be dependent on the age at onset of insulin deficiency and/or the degree of diabetic control.
2 " 4 The present studies suggest, but do not confirm, that abnormalities of linear growth in poorly controlled diabetes are the result of decreased circulating somatomedin activity due to a decrease in somatomedins and/or to an increase in somatomedin inhibitors, factors that blunt cartilage stimulation by somatomedins. 32 -33 However, the broad range of somatomedin activity found in this study also supports the concept that regulation of somatomedin activity in diabetes may be multifactorial, and includes diabetic control as only one component. The scope of this study is insufficient to elucidate any relationship between SMA and insulinization, growth hormone release, or long-term changes in control in IDD. A long-term prospective study designed to evaluate these concepts is in progress.
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